A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer

Summary

NBM-BMX is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by NatureWise. NBM-BMX is a histone deacetylase (HDAC) inhibitor and has been shown to be particularly active against HDAC8. The objectives of this study are to determine the safety profile of NBM-BMX, including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD), and to determine the Recommended Phase 2 Dose (RP2D).

Timeline

Start

2018-10-16

Primary completion

2020-04-24

Completion

2021-10-25

Drugs

Indications